Nectin-1 Expression in Colorectal Cancer: Is There a Group of Patients with High Risk for Early Disease Recurrence?


Journal

Oncology
ISSN: 1423-0232
Titre abrégé: Oncology
Pays: Switzerland
ID NLM: 0135054

Informations de publication

Date de publication:
2019
Historique:
received: 28 11 2018
accepted: 07 03 2019
pubmed: 28 3 2019
medline: 18 6 2019
entrez: 28 3 2019
Statut: ppublish

Résumé

Despite improvements in therapy of colorectal cancer, some patients will present occurrence of recurrence either locally or distantly. Tumor metastasis constitutes the major cause of cancer-associated morbidity and mortality. Nectin-1 belongs to the family of immunoglobulin-like cell adhesion molecules that contribute to the formation of cell-cell adhesions and regulate a series of cellular activities including cell polarization, differentiation, movement, proliferation, and survival. Expression of Nectin-1 in malignant tumors has been associated with aggressive tumor phenotypes. The aim of the present study was to assess Nectin-1 expression patterns in colorectal cancer and to investigate its clinical significance. Nectin-1 expression was assessed via immunohistochemistry in surgical specimens of a cohort comprised of 111 patients with primary resectable colorectal cancer. Results were correlated with clinicopathological characteristics and survival data. Progression-free survival was defined as the primary outcome of the present study. Nectin-1 was strongly expressed in the cytoplasm of colorectal cancer cells. High Nectin-1 expression was associated with advanced stage of disease (p = 0.012) and lymph node metastasis (p = 0.007). Progression-free survival of patients exhibiting high expression of Nectin-1 in the first 36 months after surgery was significantly worse compared to patients with low expression of Nectin-1 (55.7%, 95% CI = 47-70, vs. 82.1%, 95% CI = 69-93, p = 0.014) and independent of other clinicopathological characteristics (HR = 0.389, 95% CI = 0.156-0.972, p = 0.043). Nectin-1 expression in colorectal cancer is associated with a significantly worse 3-year progression-free survival identifying therefore a group of patients with high risk for early disease recurrence.

Sections du résumé

BACKGROUND BACKGROUND
Despite improvements in therapy of colorectal cancer, some patients will present occurrence of recurrence either locally or distantly. Tumor metastasis constitutes the major cause of cancer-associated morbidity and mortality. Nectin-1 belongs to the family of immunoglobulin-like cell adhesion molecules that contribute to the formation of cell-cell adhesions and regulate a series of cellular activities including cell polarization, differentiation, movement, proliferation, and survival. Expression of Nectin-1 in malignant tumors has been associated with aggressive tumor phenotypes.
OBJECTIVES OBJECTIVE
The aim of the present study was to assess Nectin-1 expression patterns in colorectal cancer and to investigate its clinical significance.
METHODS METHODS
Nectin-1 expression was assessed via immunohistochemistry in surgical specimens of a cohort comprised of 111 patients with primary resectable colorectal cancer. Results were correlated with clinicopathological characteristics and survival data. Progression-free survival was defined as the primary outcome of the present study.
RESULTS RESULTS
Nectin-1 was strongly expressed in the cytoplasm of colorectal cancer cells. High Nectin-1 expression was associated with advanced stage of disease (p = 0.012) and lymph node metastasis (p = 0.007). Progression-free survival of patients exhibiting high expression of Nectin-1 in the first 36 months after surgery was significantly worse compared to patients with low expression of Nectin-1 (55.7%, 95% CI = 47-70, vs. 82.1%, 95% CI = 69-93, p = 0.014) and independent of other clinicopathological characteristics (HR = 0.389, 95% CI = 0.156-0.972, p = 0.043).
CONCLUSION CONCLUSIONS
Nectin-1 expression in colorectal cancer is associated with a significantly worse 3-year progression-free survival identifying therefore a group of patients with high risk for early disease recurrence.

Identifiants

pubmed: 30917374
pii: 000499569
doi: 10.1159/000499569
doi:

Substances chimiques

NECTIN1 protein, human 0
Nectins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

318-325

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Athanasios Tampakis (A)

Clarunis University Center of Gastrointestinal and Liver Disorders, Department of Visceral Surgery, University Hospital Basel, Basel, Switzerland, Athantamp@hotmail.com.
2nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Athens, Greece, Athantamp@hotmail.com.

Ekaterini Christina Tampaki (EC)

2nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Athens, Greece.

Afroditi Nonni (A)

1st Department of Pathology, School of Medicine, National University of Athens, Athens, Greece.

Raoul Droeser (R)

Clarunis University Center of Gastrointestinal and Liver Disorders, Department of Visceral Surgery, University Hospital Basel, Basel, Switzerland.

Alberto Posabella (A)

Clarunis University Center of Gastrointestinal and Liver Disorders, Department of Visceral Surgery, University Hospital Basel, Basel, Switzerland.

Gerasimos Tsourouflis (G)

2nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Athens, Greece.

Konstantinos Kontzoglou (K)

2nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Athens, Greece.

Efstratios Patsouris (E)

1st Department of Pathology, School of Medicine, National University of Athens, Athens, Greece.

Markus von Flüe (M)

Clarunis University Center of Gastrointestinal and Liver Disorders, Department of Visceral Surgery, University Hospital Basel, Basel, Switzerland.

Gregory Kouraklis (G)

2nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH